8-K: CIMG Amends Debt Terms Amid Nasdaq Delisting, Reports Strong Q1 Revenue

CIMG Inc. amended its convertible note and warrant agreements following its Nasdaq delisting, while reporting significant Q1 2025 revenue growth driven by new digital health and computing power segments.

Summary

• CIMG Inc. entered into an Amended and Restated Convertible Note and Warrant Purchase Agreement on March 21, 2026, with certain non-U.S. investors, amending the terms of previously issued convertible promissory notes and warrants.
• The amendment was necessitated by the suspension of trading of the Company's common stock on The Nasdaq Stock Market LLC, effective March 6, 2026, and its current quotation on the OTC market.
• The Note Amendments revise the conversion price to be subject to a floor price of $0.10 per share and expand the definition of 'Trading Market' to include any OTC market.
• The Amended and Restated Warrants (A&R Warrants) are now exercisable for cash only at an exercise price of $0.015 per share, subject to adjustment.
• The second closing contemplated by the original purchase agreement was canceled.
• The Company committed to filing a registration statement on Form S-1 within 15 days after March 21, 2026, or as soon as practicable, to cover the resale of shares issuable upon conversion of the amended notes and exercise of the A&R Warrants.
• CIMG Inc. reported total revenue of $15,768,796 for the three months ended December 31, 2025, a substantial increase from $22,853 in the prior-year period.
• The Company achieved a continued reduction in net loss for the three months ended December 31, 2025.
• As of December 31, 2025, the Company held 730 Bitcoins with a carrying value of $63,978,821.
• Book value per share was approximately $3.6 as of December 31, 2025.
• Strategic transformation progress includes sales growth in medicine-food homology products and the official launch of computing power products in September 2025, generating revenue from enterprise customers like China Merchants Bank.
• The Company expanded its global subsidiary layout by setting up wholly-owned subsidiaries in Shenzhen and Foshan, China, and acquiring Braincon Limited and its subsidiary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with mixed sentiment. The significant revenue growth and strategic expansion into high-growth sectors are strong positives, but the Nasdaq delisting and the associated amendments to financing terms introduce substantial uncertainty and risk regarding liquidity and investor confidence.

Positives

• Total revenue for the three months ended December 31, 2025, was $15,768,796, a significant increase from $22,853 in the same period of 2024.
• Achieved a continued reduction in net loss for the three months ended December 31, 2025.
• Expanded digital asset holdings, with 730 Bitcoins valued at $63,978,821 as of December 31, 2025.
• Book value per share was approximately $3.6 as of December 31, 2025.
• Successful expansion into new business lines, including medicine-food homology products and computing power solutions.
• Secured enterprise customers for computing power products, including China Merchants Bank.
• Accelerated global subsidiary layout with new wholly-owned subsidiaries in Shenzhen and Foshan, China, and the acquisition of Braincon Limited and its subsidiary, strengthening Asia market presence and localized operations.

Negatives

• The Company's common stock was suspended from trading on The Nasdaq Stock Market LLC, effective March 6, 2026, and is currently quoted on the OTC market.
• The second closing contemplated by the Original Purchase Agreement was canceled.
• The conversion price for the notes is now subject to a floor price of $0.10 per share, which could be less favorable to investors if the stock price were to trade significantly below this level.
• The A&R Warrants are exercisable for cash only, potentially limiting flexibility for holders compared to other exercise methods.

Risks

• The value of digital asset holdings is subject to significant market volatility and may materially impact the Company's financial results.
• Risks related to the Company's ability to execute and realize the expected benefits of computing power and digital health contracts.
• Risks associated with the Company's ability to raise additional capital if needed.
• Challenges in maintaining compliance with Nasdaq listing standards and the outcome of the appeal against the Nasdaq delisting decision.
• Risks related to doing business in the Peoples Republic of China, including regulatory, legal, and currency transfer risks.
• General economic and market conditions could adversely affect the Company's operations and financial performance.
• Competition within the digital health, computing power, and digital asset sectors poses a risk to market share and profitability.

Future Outlook

CIMG Inc. plans to continue focusing on the Asia market, deepening its dual-track strategy in health consumer goods and computing power technology products. Management intends to expand online and offline sales channels for its maca series and medicine-food homology products, optimize product pricing and cost control to improve gross profit margins, and increase R&D investment in computing power products to enhance industry-specific AI data processing modules and expand its enterprise customer base. The Company also aims to actively advance follow-up financing plans, optimize its capital structure, strictly adhere to Nasdaq listing rules, and strengthen internal financial management and control systems to drive a transition from business transformation to profit growth.

Management Comments

• Alice Wang, Chairman and CEO, stated: "the Company will continue to focus on the Asia market and deepen the dual-track layout of health consumer goods and computing power technology products."
• Alice Wang added: "On the one hand, we will seek to expand the online and offline sales channels for maca series and homology of medicine and food series products, optimize product pricing and cost control, and improve the gross profit margin of core categories over time, although there can be no assurance that these efforts will be successful."
• Alice Wang further commented: "On the other hand, we will increase R&D investment in computing power products, improve the industry-specific customized development of artificial intelligence data processing modules, further expand the enterprise customer base, and raise the revenue share of the computing power business."
• Regarding capital and compliance, Alice Wang noted: "the company will actively advance the follow-up financing plan and optimize the capital structure. At the same time, we will strictly abide by the Nasdaq listing rules and rectify the previous listing compliance issues."
• Alice Wang concluded: "The company has filed an appeal against the Nasdaq delisting decision and will make every effort to maintain its listing status. In addition, the company will strengthen the construction of internal financial management and internal control systems, improve operational efficiency, and drive the Company’s transition from business transformation to profit growth."

Industry Context

StockSavvy.ai notes that CIMG Inc.'s strategic pivot towards digital health, particularly 'medicine-food homology products,' and AI-driven computing power solutions aligns with significant growth trends in technology and healthcare. The company's focus on the Asia market positions it in a region with high demand for both digital health innovations and advanced computing infrastructure. The substantial holdings in Bitcoin also reflect a strategy to leverage digital assets, a trend seen across various industries, though it introduces considerable market volatility. The acquisition of subsidiaries and expansion of product lines indicate an aggressive push to establish a strong foothold in these high-growth, technology-driven sectors.

Stakeholder Impact

• Shareholders: Face increased risk and reduced liquidity due to Nasdaq delisting and OTC market quotation. Potential for dilution from future capital raises, but also potential upside from strong business growth and strategic transformation.
• Investors (Note and Warrant Holders): Terms of their investment have been amended, including a conversion price floor and cash-only exercise for warrants, potentially altering their expected returns and flexibility.
• Customers: Benefit from the expansion of product lines in digital health and computing power solutions, including new AI data processing modules.
• Employees: Potential positive impact from business expansion and growth, leading to increased opportunities.

Next Steps

• File a registration statement on Form S-1 within 15 days after March 21, 2026, or as soon as practicable thereafter, covering the resale of shares from converted notes and exercised warrants.
• Expand online and offline sales channels for maca series and medicine-food homology products.
• Optimize product pricing and cost control to improve gross profit margins.
• Increase R&D investment in computing power products and improve industry-specific customized development of artificial intelligence data processing modules.
• Further expand the enterprise customer base for computing power business and raise its revenue share.
• Actively advance the follow-up financing plan and optimize the capital structure.
• Strictly abide by Nasdaq listing rules and rectify previous listing compliance issues.
• Continue the appeal against the Nasdaq delisting decision and make efforts to maintain listing status.
• Strengthen the construction of internal financial management and internal control systems to improve operational efficiency.

Key Dates

Recommendation

CIMG Inc. demonstrates impressive revenue growth and strategic expansion into high-growth sectors like digital health and AI computing, alongside substantial digital asset holdings. However, the recent Nasdaq delisting and the associated amendments to its financing agreements introduce significant uncertainty and risk regarding liquidity and investor confidence. While the company is actively addressing these challenges and pursuing a financing plan, the immediate future remains volatile, warranting a 'hold' position until there is clearer resolution on its listing status and sustained profitability.

Keywords

CIMG Inc., 8-K filing, Convertible Note, Warrant, Nasdaq delisting, OTC market, Q1 financial results, Revenue growth, Bitcoin holdings, Digital health, Computing power, AI data processing, Asia market, Corporate action, Private placement, Form S-1